Diversified Trust Co Takes $52,000 Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Diversified Trust Co acquired a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,574 shares of the biotechnology company’s stock, valued at approximately $52,000.

Several other institutional investors have also recently added to or reduced their stakes in IRWD. PNC Financial Services Group Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 152.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after buying an additional 2,645 shares in the last quarter. CWM LLC raised its holdings in Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 2,345 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth $91,000. GAMMA Investing LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 344.1% during the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares during the last quarter. Finally, EntryPoint Capital LLC grew its position in shares of Ironwood Pharmaceuticals by 517.4% in the first quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 8,874 shares during the period.

Insiders Place Their Bets

In other news, insider Minardo John sold 9,910 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the sale, the insider now owns 284,661 shares in the company, valued at $1,215,502.47. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IRWD. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Craig Hallum lowered their target price on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target on the stock. Finally, Wells Fargo & Company dropped their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.17.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $4.26 on Friday. The stock has a market cap of $680.49 million, a PE ratio of 106.50 and a beta of 0.48. Ironwood Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $15.70. The stock’s 50-day moving average is $4.59 and its two-hundred day moving average is $6.17.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.